Private equity investment as a divining rod for market failure: Policy responses to harmful physician practice acquisitions Erin C. Fuse Brown, Loren Adler, Erin Duffy, Paul B. Ginsburg, Mark Hall, and Samuel Valdez Tuesday, October 5, 2021
A framework for categorizing and analyzing prescription drug pricing reform options Rachel Sachs, Loren Adler, and Paul B. Ginsburg Tuesday, August 31, 2021
Government regulated or negotiated drug prices: Key design considerations Paul B. Ginsburg and Steven M. Lieberman Monday, August 30, 2021
Medicare advanced imaging payment: Dysfunctional policy making Bruce Steinwald, Paul B. Ginsburg, Caitlin Brandt, and Sobin Lee Wednesday, March 31, 2021
Prevalence and characteristics of surprise out-of-network bills from professionals in ambulatory surgery centers Erin Duffy, Loren Adler, Paul B. Ginsburg, and Erin Trish Thursday, April 16, 2020
The Elijah E. Cummings Lower Drug Costs Now Act: How it would work, how it would affect prices, and what the challenges are Paul B. Ginsburg and Steven M. Lieberman Friday, April 10, 2020
Who pays in Medicare Part D? Giving plans more skin in the game Erin Trish, Paul B. Ginsburg, Geoffrey Joyce, and Dana Goldman Thursday, November 21, 2019
“Meaningful use” of cost-measurement systems-Incentives for health care providers Merle Ederhof and Paul B. Ginsburg Wednesday, July 10, 2019
Building on the ACA to achieve universal coverage Matthew Fiedler, Henry J. Aaron, Loren Adler, Paul B. Ginsburg, and Christen Linke Young Thursday, March 28, 2019
State approaches to mitigating surprise out-of-network billing Loren Adler, Matthew Fiedler, Paul B. Ginsburg, Mark Hall, Erin Trish, Christen Linke Young, and Erin Duffy Tuesday, February 19, 2019
